Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists
Ali Mushtaq(Cleveland Clinic), Faiz Anwer(Cleveland Clinic), Omer S. Ashruf(Northeast Ohio Medical University), Shahzad Raza(Cleveland Clinic), Aneela Majeed(Cleveland Clinic), Hossam M. Ali(Cleveland Clinic), Mikhaila Rice(Cleveland Clinic), Hamza Hassan(Roswell Park Comprehensive Cancer Center), Jason Valent(Cleveland Clinic), Beth Faiman(Cleveland Clinic), Asfand Yar Cheema(Cleveland Clinic), Joslyn Rudoni(Cleveland Clinic), Maheen Ahmad(University of California, Santa Barbara), Mishaal Munir(CMH Lahore Medical College and Institute of Dentistry), Diana Basali(Cleveland Clinic), Louis Williams(Cleveland Clinic), Yara Shatnawi(Cleveland Clinic), Muhammad Asif(COMSATS University Islamabad), Sandra Mazzoni(Cleveland Clinic), Christy Samaras(Cleveland Clinic), Olga Lytvynova(Cleveland Clinic), Tara Roy(Cleveland Clinic), Jack Khouri(Cleveland Clinic), Jonathan Kissam(Cleveland Clinic), Abdullah Khan(Dana-Farber Cancer Institute)
Cited by 2
Related Papers
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
|New England Journal of Medicine|2022|457
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
|Nature Medicine|2023|239
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
|Journal of Hematology & Oncology|2024|46